Zoll to Exhibit TherOx SSO2 Therapy at Vizient Innovative Technology Exchange

Zoll Medical Corp will exhibit its TherOx SuperSaturated Oxygen (SSO₂) Therapy at the Vizient Innovative Technology Exchange on October 17, 2022 in Dallas.

Zoll’s TherOx SSO₂ Therapy is the first FDA-approved, catheter-based therapy to safely and effectively reduce infarct size (damage to heart muscle) in randomized control trials. SSO₂ is used immediately after stenting is performed for left anterior descending (LAD) ST-segment elevation (STEMI) heart attacks — the most severe type — and within six hours of symptom onset. SSO₂ delivers high levels of dissolved oxygen directly to the heart to recover damaged tissue. Data have shown that SSO₂ is associated with lower rates of heart failure and death within one year.

Vizient Inc is the nation’s largest member-driven healthcare performance improvement company. The annual Innovative Technology Exchange offers selected suppliers the unique opportunity to demonstrate their technologies to supply chain and clinical leaders from Vizient’s member hospitals and subject matter experts who serve on their supply councils. Each technology will showcase how it improves clinical outcomes, enhances safety or drives incremental improvements to health care delivery or business models.

“SSO₂ Therapy represents the first major milestone in STEMI care in almost 20 years,” said Christopher Barnabas, President of Zoll Circulation. “We feel honored to have been included in this important event and look forward to showcasing SSO₂ Therapy as the next step in improving care and outcomes for STEMI patients.”

“The Exchange is an exciting part of the Vizient Innovative Technology Program, which results in Innovative Technology contract awards for the qualified products. This signals health care providers of a product’s unique qualities,” said Kelly Flaharty, senior director of contract services, Vizient. “With only a select number of suppliers invited to demonstrate their products, it’s an honor to be invited.”

The annual Innovative Technology Exchange is part of Vizient’s Innovative Technology Program that includes product review of supplier-submitted technologies by member-led councils and task forces. Since 2003, Vizient has reviewed over 1,600 product submissions as part of its Innovative Technology Program.